MedTrace Logo

Influence of Cytosorb on Amount of Catecholamine and Mortality in Sepsis

NCT04567199 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 86

Last updated 2021-02-03

No results posted yet for this study

Summary

The aim of this retrospective study was to identify if the enrolled patient might have had a profit of Cytosorb therapy. Primarily the decline in catecholamine therapy under Cytosorb therapy will be investigated. Secondarily the outcome of surviving patients will be evaluated and compared to expected mortality due to sequential organ failure assessment (SOFA). Thirdly the patients deceased under this therapy were compared to the surviving patients.

Conditions

Interventions

OTHER

Observational, retrospective

retrospective analysis of observed results, for both study groups.

Sponsors & Collaborators

  • Medical University Innsbruck

    lead OTHER

Principal Investigators

  • Mathias Ströhle, MD · Univ.-Klinik für Allgemeine und Chirurgische Intensivmedizin

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-12-01
Primary Completion
2020-10-01
Completion
2020-12-01

Countries

  • Austria

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04567199 on ClinicalTrials.gov